Risk of breakthrough SARS-CoV-2 infection and clinical outcomes among vaccinated patients with type 2 diabetes.
Sungho BeaAhhyung ChoiJae Hyeon KimYoung Min ChoWon Suk ChoiJeong-Soo ImJu Young ShinPublished in: Diabetes, obesity & metabolism (2023)
While patients with T2D remain a vulnerable population to SARS-CoV-2 infection even after full-vaccination, full-vaccination was associated with a lower risk of adverse clinical outcomes after SARS-CoV-2 infection. These findings support the guidelines recommending patients with T2D as a priority vaccination group.